Brief: Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer
27/07/2026 12:36
BRIEF-Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer July 27 (Reuters) - Eikon Therapeutics Inc EIKN.O:
EIKON THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TELURIDE-008, A REGISTRATIONAL PHASE 2/3 TRIAL OF EIK1001 IN NON-SMALL CELL LUNG CANCER
Source text: ID:nGNX47P4Lf
Further company coverage: EIKN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eikon Therapeutics
See all newsBrief: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board
Brief: Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer
Brief: Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates
Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (updated)